Search results
Results from the WOW.Com Content Network
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue . In 2023, the company's seat in Forbes Global 2000 was 74, [ 2 ] and rank 89 on the 2024 list. [ 3 ]
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
Urbana, IL named a Top Startup City by Popular Mechanics, mainly due to the UI Research Park community [8] One of Three College-Town Incubators to watch by Inc.com in June 2013 [ 9 ] One of 12 Business Incubators Changing the World by Forbes.com in 2013 [ 10 ]
Other biotech companies on the list include Indiana's Eli Lilly , valued at $552.87 billion, and Illinois' AbbVie Inc. , valued at $273.09 billion. Several financial companies are also among the ...
This is a list of Illinois companies which includes notable companies that are headquartered in Illinois, or were previously headquartered in Illinois. In general, this list does not include companies headquartered in one of the municipalities of the Chicago metropolitan area .
AbbVie (1 C, 4 P) B. Baxter International (1 C, 9 P) W. Walgreens Boots Alliance (20 P) Pages in category "Health care companies based in Illinois"
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.It had approximately 19,000 employees. [1] Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, [2] manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication ...
On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion. [32] On 15 October, news broke suggesting AbbVie was reconsidering their proposed takeover deal due to changes in US "Tax Inversion" law [33] and on 16 October AbbVie's board recommended that shareholders vote against the deal. [34]